Limits...
Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification.

Huang ZH, Sun ZY, Gao Y, Chen PG, Liu YF, Chen YX, Li YM - Vaccines (Basel) (2014)

Bottom Line: However, the limitation of the specificity and efficiency of the synthetic tumor vaccines need further improvements.To overcome these difficulties, additional tumor-associated targets need to be identified, and optimized structural designs of vaccines need to be elaborated.In this review, we summarized the main strategies pursued in the design of synthetic tumor vaccines, such as multi-component, multivalency, antigen modification and other possible ways to improve the efficiency of synthetic tumor vaccines.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, China. huangzh05@mails.tsinghua.edu.cn.

ABSTRACT
Synthetic tumor vaccines have been proven to be promising for cancer immunotherapy. However, the limitation of the specificity and efficiency of the synthetic tumor vaccines need further improvements. To overcome these difficulties, additional tumor-associated targets need to be identified, and optimized structural designs of vaccines need to be elaborated. In this review, we summarized the main strategies pursued in the design of synthetic tumor vaccines, such as multi-component, multivalency, antigen modification and other possible ways to improve the efficiency of synthetic tumor vaccines.

No MeSH data available.


Boons’ vaccine consisting of the glycopeptide and the TLR2 agonist [34].
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4494217&req=5

vaccines-02-00549-f004: Boons’ vaccine consisting of the glycopeptide and the TLR2 agonist [34].

Mentions: Lipopeptide from bacteria is a kind of TLR2 agonists that can be used as a building block in the synthesis of vaccines [33]. Boons and co-workers built an exciting structure consisting of a bacterial lipopeptide of Pam3CSKKKK, a short MUC1 glycopeptide as the B-cell epitope and a T-helper cell epitope of KLFAVWKITYKDT from poliovirus (Figure 4). The vaccine was immunized in liposome, eliciting specific and effective immune responses [34,35]. The uptake process of vaccines by the HEK293T cell line was obviously improved by the transfection of the TLR2 gene, which proved the functions of lipopeptide in the vaccine. Furthermore, the vaccine was proven to be capable of slowing the growth of xenograft tumor [36]. Payne and co-workers synthesized tumor vaccines containing per-glycosylated MUC1 glycopeptide and lipopeptide of Pam3CS with an efficient condensation reaction, and they demonstrated that different glycosylations affected the immune response [37]. Kunz and co-workers constructed vaccines containing Pam3CKKKK and MUC1 glycopeptide, which elicited a good immune response [38]. Li and co-workers developed the method of thioether ligation to ligate peptide and Pam3CKKKK, and they synthesized a series of two-component and three-component vaccines. These vaccines improved the immune response against antigens and killed tumor cells by complement-dependent cytotoxicity (CDC) [39]. Toth and co-workers developed an oligomer of lipoamino acid as the agonist of TLR2 and further synthesized vaccines, including carbohydrate antigens and this agonist [40].


Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification.

Huang ZH, Sun ZY, Gao Y, Chen PG, Liu YF, Chen YX, Li YM - Vaccines (Basel) (2014)

Boons’ vaccine consisting of the glycopeptide and the TLR2 agonist [34].
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4494217&req=5

vaccines-02-00549-f004: Boons’ vaccine consisting of the glycopeptide and the TLR2 agonist [34].
Mentions: Lipopeptide from bacteria is a kind of TLR2 agonists that can be used as a building block in the synthesis of vaccines [33]. Boons and co-workers built an exciting structure consisting of a bacterial lipopeptide of Pam3CSKKKK, a short MUC1 glycopeptide as the B-cell epitope and a T-helper cell epitope of KLFAVWKITYKDT from poliovirus (Figure 4). The vaccine was immunized in liposome, eliciting specific and effective immune responses [34,35]. The uptake process of vaccines by the HEK293T cell line was obviously improved by the transfection of the TLR2 gene, which proved the functions of lipopeptide in the vaccine. Furthermore, the vaccine was proven to be capable of slowing the growth of xenograft tumor [36]. Payne and co-workers synthesized tumor vaccines containing per-glycosylated MUC1 glycopeptide and lipopeptide of Pam3CS with an efficient condensation reaction, and they demonstrated that different glycosylations affected the immune response [37]. Kunz and co-workers constructed vaccines containing Pam3CKKKK and MUC1 glycopeptide, which elicited a good immune response [38]. Li and co-workers developed the method of thioether ligation to ligate peptide and Pam3CKKKK, and they synthesized a series of two-component and three-component vaccines. These vaccines improved the immune response against antigens and killed tumor cells by complement-dependent cytotoxicity (CDC) [39]. Toth and co-workers developed an oligomer of lipoamino acid as the agonist of TLR2 and further synthesized vaccines, including carbohydrate antigens and this agonist [40].

Bottom Line: However, the limitation of the specificity and efficiency of the synthetic tumor vaccines need further improvements.To overcome these difficulties, additional tumor-associated targets need to be identified, and optimized structural designs of vaccines need to be elaborated.In this review, we summarized the main strategies pursued in the design of synthetic tumor vaccines, such as multi-component, multivalency, antigen modification and other possible ways to improve the efficiency of synthetic tumor vaccines.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, China. huangzh05@mails.tsinghua.edu.cn.

ABSTRACT
Synthetic tumor vaccines have been proven to be promising for cancer immunotherapy. However, the limitation of the specificity and efficiency of the synthetic tumor vaccines need further improvements. To overcome these difficulties, additional tumor-associated targets need to be identified, and optimized structural designs of vaccines need to be elaborated. In this review, we summarized the main strategies pursued in the design of synthetic tumor vaccines, such as multi-component, multivalency, antigen modification and other possible ways to improve the efficiency of synthetic tumor vaccines.

No MeSH data available.